Both non-transfusion-dependent and transfusion dependent cohorts met their respective primary and secondary endpoints
This Orphan Drug Designation from the USFDA underlines the urgent medical need to develop a therapy for sickle cell disease
The Union Budget 2026–27 accords strong priority to the upgradation and expansion of healthcare infrastructure and medical education
Receiving Orphan Drug Designation is an important milestone in the clinical development of CK0804 for myelofibrosis
The decision positions Yartemlea as the first and only approved inhibitor of the lectin pathway of complement
Coverage has been significantly strengthened across key therapeutic categories, including anti-tubercular, anti-diabetic and anti-cancer medicines, as well as iron supplements, thereby ensuring more comprehensive standardisation of medicines used under various National Health Programmes
The approval makes AQVESME the only FDA-approved therapy for anemia in both non-transfusion-dependent and transfusion-dependent alpha- or beta-thalassemia
Masitinib targets mast cells, which play a critical role in severe forms of SCD and its complications, including vaso-occlusive crises, acute chest syndrome, and pain
Orphan drug designation (ODD) by the USFDA for Desidustat, provides eligibility for a potential seven-year marketing exclusivity subject to the USFDA approval
Lenalidomide Capsules are indicated for the treatment of adult patients with Multiple myeloma
Subscribe To Our Newsletter & Stay Updated
